公开(公告)号：US20170067903A1

公开(公告)日：2017-03-09

申请号：US15309143

申请日：2015-05-05

Applicant: Baylor College of Medicine

Inventor： Bert W. O'Malley ,  Subhamoy Dasgupta ,  Nicholas Mitsiades ,  Arun Sreekumar ,  Sean E. Mcguire

IPC: G01N33/60 ,  A61K38/24 ,  A61K31/198 ,  G01N33/574 ,  A61K31/585

CPC classification number: G01N33/60 ,  A61K31/198 ,  A61K31/585 ,  A61K38/24 ,  C12Q1/16 ,  G01N33/00 ,  G01N33/48 ,  G01N33/574 ,  G01N33/57434 ,  G01N2800/50 ,  G01N2800/52 ,  G21H5/02

Abstract: Embodiments of the disclosure include methods and compositions for treatment of prostate cancer, including metastatic prostate cancer or prostate cancer at risk for developing into metastatic prostate cancer, by providing an effective therapy to an individual that has been determined to have elevated levels of SRC-2 (also known as NCOA2, GRIP1 TIF2). In particular cases, sample from an individual known to have prostate cancer is assayed for the risk for developing metastatic prostate cancer and the individual is provided an effective therapy upon determination of elevated levels of SRC-2.

Abstract translation: 本公开的实施方案包括用于治疗前列腺癌的方法和组合物，包括转移性前列腺癌或具有发展为转移性前列腺癌风险的前列腺癌，通过向被确定具有升高的SRC-2水平的个体提供有效治疗 （也称为NCOA2，GRIP1 TIF2）。 在特定情况下，测定已知具有前列腺癌的个体的样品用于发展转移性前列腺癌的风险，并且在确定SRC-2水平升高时提供有效的治疗方法。

公开(公告)号：US10227656B2

公开(公告)日：2019-03-12

申请号：US15034467

申请日：2014-11-07

Applicant: Baylor College of Medicine

Inventor： Bin He ,  Rainer B. Lanz ,  Nicholas Mitsiades ,  Qin Feng

IPC: C12Q1/6886 ,  G01N33/574

Abstract: Embodiments of the present disclosure concern methods and compositions for prognosis, diagnosis, and/or treatment of prostate cancer or breast cancer, for example. Certain embodiments of the disclosure concern assaying for the expression level of TDRD1. Particular embodiments concern treating an individual with a particular cancer therapy when the expression level of TDRD1 is overexpressed.

公开(公告)号：US20160281170A1

公开(公告)日：2016-09-29

申请号：US15034467

申请日：2014-11-07

Applicant: Baylor College of Medicine

Inventor： Bin He ,  Rainer B. Lanz ,  Nicholas Mitsiades ,  Qin Feng

IPC: C12Q1/68 ,  G01N33/574

CPC classification number: C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/158 ,  G01N33/57415 ,  G01N33/57434 ,  G01N33/5748 ,  G01N33/57496 ,  G01N2333/4703

Abstract: Embodiments of the present disclosure concern methods and compositions for prognosis, diagnosis, and/or treatment of prostate cancer or breast cancer, for example. Certain embodiments of the disclosure concern assaying for the expression level of TDRDl. Particular embodiments concern treating an individual with a particular cancer therapy when the expression level of TDRDl is overexpressed.

Abstract translation: 本公开的实施方案涉及例如用于预后，诊断和/或治疗前列腺癌或乳腺癌的方法和组合物。 本公开的某些实施方案涉及测定TDRD1的表达水平。 当TDRD1的表达水平过度表达时，具体实施方案涉及治疗具有特定癌症治疗的个体。

公开(公告)号：US10082510B2

公开(公告)日：2018-09-25

申请号：US15309143

申请日：2015-05-05

Applicant: Baylor College of Medicine

Inventor： Bert W. O'Malley ,  Subhamoy Dasgupta ,  Nicholas Mitsiades ,  Arun Sreekumar ,  Sean E. Mcguire

IPC: G01N33/60 ,  G01N33/00 ,  G01N33/48 ,  G01N33/574 ,  A61K31/585 ,  A61K38/24 ,  C12Q1/16 ,  G21H5/02 ,  A61K31/198

CPC classification number: G01N33/60 ,  A61K31/198 ,  A61K31/585 ,  A61K38/24 ,  C12Q1/16 ,  G01N33/00 ,  G01N33/48 ,  G01N33/574 ,  G01N33/57434 ,  G01N2800/50 ,  G01N2800/52 ,  G21H5/02

Abstract: Embodiments of the disclosure include methods and compositions for treatment of prostate cancer, including metastatic prostate cancer or prostate cancer at risk for developing into metastatic prostate cancer, by providing an effective therapy to an individual that has been determined to have elevated levels of SRC-2 (also known as NCOA2, GRIP1 TIF2). In particular cases, sample from an individual known to have prostate cancer is assayed for the risk for developing metastatic prostate cancer and the individual is provided an effective therapy upon determination of elevated levels of SRC-2.

公开(公告)号：US20230167101A1

公开(公告)日：2023-06-01

申请号：US17918074

申请日：2021-04-08

Applicant: BAYLOR COLLEGE OF MEDICINE

Inventor： Yongcheng Song ,  Fangrui Wu ,  Shenyou Nie ,  Yuanda Hua ,  Yi-Lun Lin ,  Salma Kaochar ,  Nicholas Mitsiades

IPC: C07D409/12 ,  A61P35/00 ,  C07D405/14 ,  C07D409/14 ,  C07D333/20 ,  C07D405/12 ,  C07D417/12

CPC classification number: C07D409/12 ,  A61P35/00 ,  C07D333/20 ,  C07D405/12 ,  C07D405/14 ,  C07D409/14 ,  C07D417/12

Abstract: Embodiments of the present disclosure pertain to compositions that include a compound that inhibits the histone acetyl transferase activity of a protein, such as p300 and/or CBP. Further embodiments of the present disclosure pertain to methods of inhibiting the histone acetyl transferase activity of a protein by exposing the protein to a composition that contains one or more of the compounds of the present disclosure. The compositions of the present disclosure may be exposed to a protein in vitro or in vivo. Additional embodiments of the present disclosure pertain to methods of treating a cancer in a subject by administering a composition of the present disclosure to the subject in order to treat the cancer.